---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000081"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:21:45.445236+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics stockholders approve doubling authorized shares to 200M

## Summary
- Stockholders voted 42,389,461 for, 790,853 against, 71,655 abstain to increase authorized common shares to 200,000,000.
- Authorization increased from 100,000,000 to 200,000,000 shares of common stock.
- Special Meeting held September 17, 2024; quorum of 43,251,969 shares (57.67%) present.
- Proposal also included approval of adjournments if needed, passed with 42,447,035 votes for.

## SEC filing metadata
- accession: 0001842952-24-000081
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000081/0001842952-24-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000081/cntx-20240917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000081
- JSON: https://secwatch.observer/filing/0001842952-24-000081.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.